Omeros (OMER) – FDA
-
Omeros (OMER) says narsoplimab did not achieve statistically significant improvement over placebo in Phase 3 trial
-
Omeros (OMER) Announces Late-Breaking Presentation of OMS906 Data
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to OMER Stock Lookup